|Bid||0.00 x 3100|
|Ask||182.20 x 800|
|Day's Range||174.55 - 182.44|
|52 Week Range||119.29 - 184.83|
|Beta (5Y Monthly)||1.24|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A Relative Strength Rating upgrade for Alnylam Pharmaceuticals shows improving technical performance. Will it continue?
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F filings […]